Project Grant R43HL172384
Award Date
9/20/24
Completion Date
3/19/26
Dollars Obligated
$265K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Detroit, MI 48202, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $483,852 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a high-throughput platform to measure the equilibrium and kinetics of hemoglobin polymerization in single red blood cells. This platform will enable the optimization of emerging sickle cell disease treatments, including gene therapy, gene...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $400,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant will support the development of a new analytical testing device to precisely characterize lipoprotein particles in blood. Lipoproteins are key indicators of cardiovascular disease risk, as some classes contribute to the buildup of plaque in...
This federal Project Grant award of $827,753.90, awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of thiol isomerases in promoting redox-sensitive vaso-occlusion in sickle cell disease (SCD). The award enables the awardee, Bloodworks, an independent nonprofit organization in Seattle, to conduct a multi-year research project focused on mechanistically examining how thiol...
This $568,264 Project Grant (R41HL178144) from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the manufacturing of designer red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). The primary goal is to develop a scalable, cost-efficient bioprocess to produce these specialized RBCs, which can be used as reagents to identify rare antibodies in patients requiring blood transfusions,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 in funding to Gigamune, Inc. to develop an in vivo gene therapy for the treatment of sickle cell disease. The project aims to test a novel lentiviral vector technology for editing hematopoietic stem cells to knockout the BCL11A enhancer or express an anti-sickling beta-globin gene. This Phase I SBIR project will evaluate the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,095,816 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The DNA Medicine Institute, Inc. to develop a rapid, 5-minute point-of-care test that can measure anti-Factor Xa activity and hemoglobin levels. This diagnostic tool is intended to guide emergency management for patients on direct oral anticoagulants, potentially enabling quicker delivery of life-saving interventions. The 2-year project,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the effects of sickle red blood cells (RBCs) on neutrophil activation and phenotypes in sickle cell disease. The research aims to delineate the specific characteristics of sickle RBCs that induce neutrophil activation, as well as the downstream consequences of these sickle...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $297,587 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to General Fluidics Corporation to validate the performance of the AXESS system, a novel point-of-need clinical chemistry and hematology platform. The goal is to demonstrate equivalence between the AXESS system's results and those obtained from standard venous blood testing for a basic metabolic panel and complete blood count, using matched capillary and...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $321,363 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Nucleusrx, Inc. located in Cranbury, NJ. The purpose of this 1-year project is to develop and test Nucleusrx's virtual care platform and remote intervention tool targeting post-acute care heart failure (HF) patients. The goal is to provide a safe and cost-effective discharge transition...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $608,126 to the Regents of the University of Minnesota to conduct research on discovery and validation of single cell biomarkers for clinical outcomes in sickle cell disease. The primary objectives are to: 1) define the relationship between sickle cell disease adverse clinical outcomes and single cell biochemical and mechanical properties...